US Government Suppresses Vaccine Safety Studies, Raising Transparency Concerns

Executive Summary of the Suppression Allegations

Last week the New York Times and Washington Post disclosed that the FDA directed the withdrawal of two Covid‑19 vaccine safety studies and blocked a Shingrix safety abstract, despite peer‑review acceptance. The actions raise serious questions about political interference in vaccine safety surveillance.

FDA Withdraws Peer‑Reviewed Vaccine Safety Studies

In October, FDA scientists were instructed to pull two manuscripts that had been accepted by the journals Drug Safety and Vaccine. A February decision prevented the submission of Shingrix safety abstracts to a major drug‑safety conference. The agency commissioned the work, received the findings, but has not released them.

Scale of the Suppressed Studies and Their Findings

• Study 1 examined 7.5 million Medicare beneficiaries for 14 pre‑specified adverse outcomes after 2023‑2024 Covid‑19 vaccination, using a self‑controlled case‑series design with up to 90 days follow‑up. Only anaphylaxis (~1 per million Pfizer‑BioNTech doses) rose above statistical noise.
• Study 2 analyzed 4.2 million recipients aged 6 months to 64 years, confirming rare febrile‑seizure and myocarditis signals already on product labels.
• The Shingrix analysis, covering millions, reaffirmed a low but elevated Guillain‑Barré risk noted on the vaccine’s package insert.

Implications for Public‑Health Transparency Ahead of the World Cup

The timing coincides with the 2026 FIFA World Cup across 11 U.S. host cities, a period when measles cases have surged to >9,000 in Mexico and Canada lost measles‑elimination status. The CDC has lost roughly a quarter of its workforce in the past year and has faced editorial pressure on its weekly reports. Suppressing reassuring safety data while allowing unsubstantiated adverse‑event claims to circulate undermines clinician confidence and public‑health surveillance.

Future Outlook for Vaccine Surveillance and Policy

If political appointees continue to block peer‑reviewed findings, the credibility of federal vaccine monitoring could erode, prompting calls for independent oversight or legislative action. Transparency of the existing data may become a focal point for lawmakers and health‑care professionals as the World Cup progresses and respiratory clusters emerge.